Profiting From the Biotech Boom

Make no mistake, we're entering a golden age of pharmaceutical development. From mRNA to monoclonal antibodies, modern medical science is scoring the biggest breakthroughs since the advent of penicillin. Make no mistake, we're entering a golden age of pharmaceutical development. From mRNA to monoclonal antibodies, modern medical science is scoring the biggest breakthroughs since the advent of penicillin. [Energy and Capital logo] Profiting From the Biotech Boom By Jason Simpkins Written May 17, 2021 Make no mistake, we're entering a golden age of pharmaceutical development. From mRNA to monoclonal antibodies, modern medical science is scoring the biggest breakthroughs since the advent of penicillin. And whereas new medicine could often take 10 years to commercialize, complex avant-garde coronavirus vaccines charged through pipelines at record speed. Indeed, we've finally seen how quickly things can move and what can truly be achieved when the government and private sector collaborate on a common, urgent goal. The results have been a boon for humanity and investors. Pfizer (NYSE: PFE) dug itself out of the COVID collapse, climbing 45% on the strength of its vaccine development. The company's success culminated in an massive earnings beat recently. Pfizer reported earnings of $0.93 per share for the first quarter — a 47% surge from last year that easily topped the FactSet consensus estimate of $0.77 a share. Revenue rose 42% to $14.6 billion. More importantly, though, the company vastly increased its projected revenue from its COVID vaccine, saying it now expects $26 billion in sales this year, up from the $15 billion it had projected in February. It also expects to have the capacity to manufacture 3 billion doses of the vaccine in 2022 and is negotiating contracts with governments for supply in 2022 and beyond. [Pfizer Covid Timeline] FREE Training Event: How to Become a Biotech Trader On May 20, Keith Kohl is going to show you the strategy that’s allowed him to clock massive winners of 171%, 77%, and 225% on fast-moving biotech trades. Sometimes they only take a week to play out... but the returns can be massive. [Click here to register for the grand reveal.]( The company has a plethora of other remedies in the works as well. As a result, Pfizer raised its full-year guidance and is now projecting between $70.5 billion–$72.5 billion in annual revenue and net earnings of $3.55–$3.65 per share. BioNTech (NASDAQ: BNTX), Pfizer's partner on the COVID vaccine, has done even better for itself, having already surged 114% this year. It also beat earnings estimates with eye-popping growth figures. Earnings per share rose 2,134.62% over the past year to $5.29, while revenue jumped 7,995.18% to $2.5 billion. Astonishing when you consider the company was losing money a year ago. But now the company has signed contracts to deliver 1.8 billion doses of its COVID vaccine in 2021. That would generate more than $15 billion in sales, which is well ahead of BioNTech stock analysts' forecast for $10.5 billion in full-year sales. Better still, BioNTech believes its vaccine will work against India’s vicious “double mutant” strain of COVID. The company has tested its two-dose vaccine, which is currently not available in India, against similar “double mutants” and researchers are confident the shot will still be protective based on the data. And, as with Pfizer, BioNTech raised its guidance and pointed to other promising initiatives. It's expanding with a new mRNA manufacturing plant in Singapore that will manufacture hundreds of millions of doses of mRNA-based vaccines each year. Besides its mRNA-based vaccines, BioNTech also has a pipeline of cancer programs and infectious disease programs. [Biontech Pipeline]So again, if you think companies like Pfizer and BioNTech will recede along with the threat of COVID, think again. And on top of that there's a host of other companies joining them in this bold, new, 21st-century biotech boom. This New Battery Could Dethrone Tesla [twa electric glass finger]( A brand-new type of battery is about to flood the markets and dethrone Tesla forever. This battery is up to 10 times more powerful than Tesla’s famed lithium-ion battery and is absolutely tiny — roughly the size of a drop of water. This is a rare second chance to take part in a world-shifting innovation. [Click here to see the details.]( Of course, investing in the sector isn't always as easy as singling out stocks like these. It takes great attention to detail, the ability to monitor drug development, and a full understanding of the catalysts that propel biotech stocks to big-time gains. That's the only way to truly maximize your profit — not just ride some coattails after the fact. Fortunately, my friend, colleague, and renowned biotech expert Keith Kohl has developed a simple system that can easily hand even the most novice biotech investor double- and triple-digit profits. In fact, if you're capable of reading a calendar, then guess what? You're qualified. It's that easy to isolate life-changing gains in this seemingly byzantine sector. And I can prove it. Keith is hosting [a special, one-time training event on May 20]( (this Thursday) in which he'll provide all the details. And it's completely FREE. You literally have nothing to lose and everything to gain. You're not going to find a better breakdown of the biotech sector anywhere. And the profit potential is enormous. [So check out the details here](. Fight on, [Jason Simpkins Signature] Jason Simpkins --------------------------------------------------------------- The Tiny Stock Behind This 5G Linchpin Do you see that tiny module pictured above, next to the quarter? That tiny module is what makes the entire 5G rollout possible. Without it, the 5G revolution wouldn’t be a reality. And this little-known company I've uncovered that produces these tiny chips could skyrocket in 2021. Why? You see, these tiny pieces of technology are part of a government-mandated program I’m calling 5G-Volta. This program is projected to be worth as much as $1.5 trillion! This is the biggest 5G opportunity that no one is talking about. Now that this program is rolling out, early investors are poised to reap windfall profits. I’m talking about possibly turning every $1,500 invested into a fortune. I’ve put together all my research about this government-mandated program along with the name of this tiny, game-changing stock in a report that I want to share with you right now. [Click here to find out how to get your free report now!]( Browse Our Archives [Up to 144 New Stock Opportunities Make This Sector Ripe for Profits]( [What They're Not Telling You About the Colonial Pipeline Cyberattack]( [How to Trade the FDA Approval Game]( [Investing in the End of Pandemics]( [Bold Prediction: Bitcoin to $125,000]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2021, [Angel Publishing LLC](. All rights reserved. 3 E Read Street, Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.